Correlation Between the Crohn's Disease Activity and Harvey-Bradshaw Indices in Assessing Crohn's Disease Severity

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 4, 2010, Pages 357-363

  Vermeire, Severine ^a   Schreiber, Stefan ^b   Sandborn, William J ^c   Dubois, Cécile ^d   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF KIEL   (Germany)

^c MAYO CLINIC   (United States)

^d UCB Inc   (Belgium)

Author keywords

CDAI; Correlation; Crohn's Disease; HBI

Indexed keywords

CERTOLIZUMAB PEGOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CROHN DISEASE; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; MIDDLE AGED; POLYETHYLENE GLYCOLS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77949652854     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.01.001     Document Type: Article

References (28)

1. Loftus C.G., Loftus Jr. E.V., Harmsen W.S., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 13 (2007) 254-261
2. Shivananda S., Lennard-Jones J., Logan R., et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39 (1996) 690-697
3. Jacobsen B.A., Fallingborg J., Rasmussen H.H., et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol 18 (2006) 601-606
4. Lapidus A. Crohn's disease in Stockholm county during 1990-2001: an epidemiological update. World J Gastroenterol 12 (2006) 75-81
5. Rubin G.P., Hungin A.P., Kelly P.J., et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 14 (2000) 1553-1559
6. Saro Gismera C., Lacort Fernandez M., Arguelles Fernandez G., et al. Incidence and prevalence of inflammatory bowel disease in Gijon, Asturias, Spain. [in Spanish]. Gastroenterol Hepatol 23 (2000) 322-327
7. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
8. Harvey R.F., and Bradshaw J.M. A simple index of Crohn's disease activity. Lancet 1 (1980) 514
9. Su C., Lichtenstein G.R., Krok K., et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 126 (2004) 1257-1269
10. Jørgensen L.G., Fredholm L., Hyltoft P.P., et al. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)?. Clin Chem Lab Med 43 (2005) 403-411
11. Sands B.E., and Ooi C.J. A survey of methodological variation in the Crohn's disease activity index. Inflamm Bowel Dis 11 (2005) 133-138
12. Choy E.H., Hazleman B., Smith M., et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41 (2002) 1133-1137
13. Keystone E., Choy E.H., Kalden J., et al. CDP870, a novel, PEGylated, humanized TNF-a inhibitor is effective in treating the signs and symptoms of rheumatoid arthritis (RA). Arthritis Rheum 44 (2001) 2946
14. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
15. Weir N., Athwal D., Brown D., et al. A new generation of high-affinity humanized PEGylated Fab' fragment anti-tumor necrosis factor-a monoclonal antibodies. Therapy 3 (2006) 535-545
16. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
17. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
18. Schreiber S., Hanauer S., Feagan B., et al. Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: PRECiSE 3 efficacy results. Gastroenterology 132 Suppl 2 (2007) A504
19. Sandborn W.J., Hanauer S.B., Rutgeerts P.J., et al. Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results. Gastroenterology 132 Suppl 2 (2007) A505
20. Best W.R. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 12 (2006) 304-310
21. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
22. Greenbloom S.L., Steinhart A.H., and Greenberg G.R. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 12 (1998) 53-56
23. Leiper K., Morris A.I., and Rhodes J.M. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 14 (2000) 801-806
24. Cezard J.P., Nouaili N., Talbotec C., et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 36 (2003) 632-636
25. Hafraoui S., Dewit O., Marteau P., et al. Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate [in French]. Gastroenterol Clin Biol 26 (2002) 17-22
26. Lemann M., Chamiot-Prieur C., Mesnard B., et al. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 10 (1996) 309-314
27. Lemann M., Zenjari T., Bouhnik Y., et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 95 (2000) 1730-1734
28. Arber N., Odes H.S., Fireman Z., et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 20 (1995) 203-206